Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Am Heart J. 2022 Jul;249:57-65. doi: 10.1016/j.ahj.2022.04.002. Epub 2022 Apr 8.
Reduced venous return is an important trigger of vasovagal syncope (VVS). Elastic compression stockings (ECS) can modify venous return and be of therapeutic interest; however, evidence for ECS efficacy in VVS is scarce. This randomized controlled trial was designed to address the issue.
COMFORTS-II is a multicenter, triple-blind, parallel design, randomized controlled trial aimed to assess the efficacy of ECS in preventing VVS recurrences. Using central online randomization, 268 participants will be allocated to 2 arms (1:1 ratio), wearing intervention ECS (25-30 mm Hg pressure) or sham ECS (≤10 mm Hg pressure). All participants will receive standard VVS treatment in the form of education, and lifestyle modification recommendations (drinking 2-3 l/d of fluids and consuming 10 g/d-roughly half a tablespoon-of table salt). Adherence to ECS treatment will be evaluated through diary sheets, and compared between study arms. Follow-up continues for 1 year, and is conducted via a 24/7 phone line available to patients and trimonthly visits. The co-primary outcomes are proportion of participants with any syncopal recurrence and time to first syncopal episode. Secondary outcomes include frequency of VVS spells, time intervals between recurrences, and incidence of any patient-reported adverse effects.
To the best of our knowledge, COMFORTS-II is the first clinical trial to assess ECS efficacy among patients with VVS, addressing an important gap in evidence for VVS treatments.
静脉回流减少是血管迷走性晕厥(VVS)的重要触发因素。弹性压缩袜(ECS)可以改变静脉回流,具有治疗意义;然而,ECS 在 VVS 中的疗效证据很少。本随机对照试验旨在解决这一问题。
COMFORTS-II 是一项多中心、三盲、平行设计、随机对照试验,旨在评估 ECS 预防 VVS 复发的疗效。使用中央在线随机化,将 268 名参与者分配到 2 个臂(1:1 比例),分别穿着干预性 ECS(25-30mmHg 压力)或假性 ECS(≤10mmHg 压力)。所有参与者将接受标准的 VVS 治疗,包括教育和生活方式改变建议(每天饮用 2-3 升液体和摄入 10 克/天-大约半勺盐)。通过日记表评估 ECS 治疗的依从性,并与研究臂进行比较。随访持续 1 年,通过 24/7 电话热线和每三个月一次的就诊进行。主要结局是任何晕厥复发的参与者比例和首次晕厥发作时间。次要结局包括 VVS 发作频率、复发之间的时间间隔以及任何患者报告的不良事件的发生率。
据我们所知,COMFORTS-II 是评估 VVS 患者 ECS 疗效的第一项临床试验,填补了 VVS 治疗证据的重要空白。